

March 20, 2018



BioCorRx Comments on President Donald J. Trump's Initiative to Stop Opioid Abuse

ANAHEIM, CA, March 20, 2018 (GLOBE NEWSWIRE) --

BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today commented on President Trump's initiative to stop opioid abuse and address factors fueling the opioid crisis, including over-prescription, illicit drug supplies, and insufficient access to evidence-based treatment, primary prevention, and recovery support services. The [White House](#) issued a fact sheet on March 19, 2018 addressing the driving forces of the opioid crisis. According to the fact sheet, one of the initiatives "will help those struggling with addiction through evidence-based treatment and recovery support services." Medication-assisted treatment (MAT) is evidence-based and one of the medications used in MAT is naltrexone. The fact sheet specifically discusses naltrexone use in the criminal justice system for offenders struggling with substance use disorder.

Brady Granier, CEO of BioCorRx, Inc., stated, "We appreciate President Trump's proactive stand in addressing the opioid epidemic. We have been an early leader in the field of MAT therapy specific to naltrexone for opioid use disorder (OUD) and expect these new initiatives will help spur wider adoption of MAT. We strongly believe the most effective treatment for OUD is the combination of medication with cognitive behavioral therapy (CBT) and peer support, which has proven highly effective for those patients treated with our BioCorRx® Recovery Program. Our program was recently adopted in Philadelphia in collaboration with One Day at a Time (ODAAT), a program funded by the city of Philadelphia and state of Pennsylvania. As previously announced, we have already met with the FDA and received positive feedback on BICX102, our sustained release naltrexone implant. The FDA deemed the project acceptable for a 505(b)(2) pathway, which we believe will be a more abbreviated and cost-effective route to approval. We have received strong support from the National Institute on Drug Abuse (NIDA) and we are currently finalizing our application for a NIDA grant. We look forward to the implementation of the President's initiatives, which we believe will have a meaningful impact on combating the opioid crisis."

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The

Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.
investors@BioCorRx.com
714-462-4880

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com



Source: BioCorRx Inc